Compare HAFC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | CERT |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.2M | 860.9M |
| IPO Year | 2000 | 2020 |
| Metric | HAFC | CERT |
|---|---|---|
| Price | $30.06 | $4.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $32.17 | $11.67 |
| AVG Volume (30 Days) | 219.8K | ★ 3.0M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | 22.44 | ★ 87.50 |
| EPS | ★ 0.75 | N/A |
| Revenue | $270,165,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $18.65 | $4.18 |
| Revenue Next Year | $7.28 | $5.39 |
| P/E Ratio | $39.32 | ★ N/A |
| Revenue Growth | ★ 15.28 | 8.75 |
| 52 Week Low | $21.84 | $4.45 |
| 52 Week High | $31.33 | $13.88 |
| Indicator | HAFC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 29.39 |
| Support Level | $29.20 | N/A |
| Resistance Level | $30.47 | $6.47 |
| Average True Range (ATR) | 0.59 | 0.31 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 64.78 | 11.22 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.